1. Home
  2. ACET vs AIRE Comparison

ACET vs AIRE Comparison

Compare ACET & AIRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.51

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Logo reAlpha Tech Corp.

AIRE

reAlpha Tech Corp.

N/A

Current Price

$0.30

Market Cap

56.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ACET
AIRE
Founded
1947
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
56.9M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
ACET
AIRE
Price
$7.51
$0.30
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$65.33
$2.00
AVG Volume (30 Days)
161.1K
1.3M
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
59.82
N/A
EPS
N/A
N/A
Revenue
N/A
$948,420.00
Revenue This Year
N/A
$470.21
Revenue Next Year
N/A
$143.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.14
52 Week High
$9.05
$1.55

Technical Indicators

Market Signals
Indicator
ACET
AIRE
Relative Strength Index (RSI) 55.37 38.45
Support Level $6.54 $0.29
Resistance Level $8.46 $0.35
Average True Range (ATR) 0.47 0.02
MACD -0.00 0.00
Stochastic Oscillator 61.05 32.38

Price Performance

Historical Comparison
ACET
AIRE

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

About AIRE reAlpha Tech Corp.

ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.

Share on Social Networks: